US Patent Issued to Vifor (International) on Jan. 27 for "Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (TDT)" (Swiss Inventors)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,533,348, issued on Jan. 27, was assigned to Vifor (International) AG (St. Gallen, Switzerland).

"Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (TDT)" was invented by Vania Manolova (St. Gallen, Switzerland), Naja Nyffenegger (St. Gallen, Switzerland), Patrick Altermatt (St. Gallen, Switzerland) and Franz Durrenberger (Dornach, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for treating transfusion-dependent Beta-thalassemia."

The patent was filed on July 17, 2020, under Application No. 17/627,907.

*...